In addition, both studies noted that EZH2 inhibition resulted in positive changes in the CD8+ T cell antitumor immune responses, including an increase in the frequency of IFNγ-producing CD8+ T cells and reduced inhibitory marker expression on tumor-infiltrating T cells (48, 49). Here, CD8A is linked to neoplasm.